Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind trial of recombinant 15-valent HPV vaccine in healthy women aged 18-45 years
CTR20250975Phase 2Active
- Sponsor
- Beijing Health Guard
- Start
- Apr 2025
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of human papillomavirus 15-valent vaccine in human papillomavirus infection, cervical intraepithelial neoplasia (CIN), vulvar intraepithelial neoplasia (VIN) and 7 more (5 arms), sponsored by Beijing Health Guard. Primary endpoint: Neutralizing antibody GMT for vaccine-related HPV types. Started Apr 2025; status: active.
02
Drugs
human papillomavirus 15-valent vaccine
03
Conditions
human papillomavirus infectioncervical intraepithelial neoplasia (CIN)vulvar intraepithelial neoplasia (VIN)vaginal intraepithelial neoplasia (VAIN)anal intraepithelial neoplasia (AIN)
Beyond the preview
Go deeper on CTR20250975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250975.